Comparison · NCT02173379-37dd68a0
Absorb BVS vs XIENCE: TLF at 1-year, Non-inferiority Against the Control
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Absorb BVS vs XIENCE: TLF at 1-year, Non-inferiority Against the Control. Trial comparisons, record NCT02173379-37dd68a0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02173379-37dd68a0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0781 | 0.0645 | 0.0943 | wilson | |
| Risk in group 2 | 0.0645 | 0.0522 | 0.0793 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0137 | -0.00645 | 0.034 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.21 | 0.914 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 1.23 | 0.908 | 1.67 | log | |
| Number needed to treat, for one more participant with the outcome on Absorb BVS than on XIENCE | 73.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Absorb BVS | Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System | 98 | 1,254 | OG000 |
| Group 2 | XIENCE | Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only) | 82 | 1,272 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- TLF at 1-year, Non-inferiority Against the Control
- Description
- One-sided p-value by using Farrington-Manning non-inferiority test will be used with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.
- Time frame
- 1 year
- Population
- ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Source ClinicalTrials.gov
Trial
- Title
- Absorb IV Randomized Controlled Trial
- NCT number
- NCT02173379
- Phases
- NA
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Interventions
- Absorb BVS, XIENCE
- Lead sponsor
- Abbott Medical Devices
- Results first posted
- 2018-07-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02173379?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02173379-37dd68a0